Open access
Open access
Powered by Google Translator Translator

Oncology – Lung

Single-arm phase II study: EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma.

24 Jun, 2022 | 10:49h | UTC

EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study – The Lancet Oncology (link to abstract – $ for full-text)

 


RCT: Furmonertinib vs. gefitinib as first-line therapy for patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer.

9 Jun, 2022 | 10:25h | UTC

Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study – The Lancet Respiratory Medicine (link to abstract – $ for full-text)

 


#ASCO22 – Phase 2 single-arm study: Adagrasib in non–small-cell lung cancer harboring a KRASG12C mutation.

6 Jun, 2022 | 11:15h | UTC

Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Targeted drug achieves 43% response rate in KRAS-mutated lung cancer – Dana-Farber Cancer Institute

 


#ASCO22 – Phase II RCT: Ramucirumab and pembrolizumab vs. standard of care in advanced non–small-cell lung cancer previously treated with immunotherapy.

6 Jun, 2022 | 11:14h | UTC

Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A – Journal of Clinical Oncology

Commentary: New drug combination lengthened survival for some with lung cancer – SWOG Cancer Research Network

 

Commentary on Twitter

 


Summary of best evidence for enhanced recovery after surgery for patients undergoing lung cancer operations.

3 Jun, 2022 | 11:02h | UTC

Summary of best evidence for enhanced recovery after surgery for patients undergoing lung cancer operations – Asia-Pacific Journal of Oncology Nursing

Related:

Guidelines for enhanced recovery after lung surgery: recommendations of the Enhanced Recovery After Surgery (ERAS®) Society and the European Society of Thoracic Surgeons (ESTS) – European Journal of Cardio-Thoracic Surgery

Enhanced recovery programs in lung cancer surgery: systematic review and meta-analysis of randomized controlled trials – Cancer Management and Research

Clinical guidelines on perioperative management strategies for enhanced recovery after lung surgery – Translational Lung Cancer Research

Systematic Review and Meta-Analysis of Randomized, Controlled Trials on Preoperative Physical Exercise Interventions in Patients with Non-Small-Cell Lung Cancer – Cancers

Preoperative exercise training for patients with non‐small cell lung cancer – Cochrane Library

 


Cardiac metastasis from solid cancers: a 35-year single-center autopsy study.

3 Jun, 2022 | 10:54h | UTC

Cardiac Metastasis From Solid Cancers: A 35-Year Single-Center Autopsy Study – Archives of Pathology & Laboratory Medicine

 


M-A: Stereotactic radiosurgery vs. whole brain radiotherapy in patients with intracranial metastatic disease and small-cell lung cancer.

30 May, 2022 | 10:41h | UTC

Stereotactic radiosurgery versus whole brain radiotherapy in patients with intracranial metastatic disease and small-cell lung cancer: a systematic review and meta-analysis – The Lancet Oncology (link to abstract – $ for full-text)

News Release: Meta-Analysis Shows Targeted Radiation Therapy May Be as Effective as Standard Care for Small Cell Lung Cancer Patients with Brain Metastases – St. Michael’s Hospital

 


Single-arm, phase II trial: overall survival and biomarker analysis of neoadjuvant Nivolumab plus chemotherapy in operable stage IIIA non–small-cell lung cancer.

30 May, 2022 | 10:39h | UTC

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial) – Journal of Clinical Oncology

 

Commentary on Twitter

 


RCT: Tiragolumab plus atezolizumab vs. placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer.

27 May, 2022 | 11:11h | UTC

Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study – The Lancet Oncology (link to abstract – $ for full-text)

Commentary: First-line tiragolumab–atezolizumab promising for PD-L1-positive advanced NSCLC – Medicine Matters

 


RCT: Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer.

27 May, 2022 | 11:09h | UTC

Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

 


RCT: Aumolertinib vs. Gefitinib as first-line therapy for locally advanced or metastatic non-small-cell lung cancer with EGFR Exon 19 deletion or L858R mutations.

26 May, 2022 | 10:10h | UTC

AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or Metastatic Non–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations – Journal of Clinical Oncology

 

Commentary on Twitter

https://creativecommons.org/licenses/by-nc-nd/4.0/

 


Update on image-guided thermal lung ablation: Society guidelines, therapeutic alternatives, and postablation imaging findings.

4 May, 2022 | 08:14h | UTC

Update on Image-Guided Thermal Lung Ablation: Society Guidelines, Therapeutic Alternatives, and Postablation Imaging Findings – American Journal of Roentgenology

 


RCT: Segmentectomy resulted in better outcomes than lobectomy in small-sized peripheral non-small-cell lung cancer.

25 Apr, 2022 | 01:03h | UTC

Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial – The Lancet (link to abstract – $ for full-text)

 


RCT: Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer.

12 Apr, 2022 | 08:54h | UTC

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer – New England Journal of Medicine

News Release: Immunotherapy Plus Chemotherapy Before Surgery Improves Outcomes for Patients with Lung Cancer – Johns Hopkins Medicine

 

Commentary on Twitter

 


Association of computed tomography screening with lung cancer stage shift and survival in the United States: quasi-experimental study.

31 Mar, 2022 | 08:23h | UTC

Association of computed tomography screening with lung cancer stage shift and survival in the United States: quasi-experimental study – The BMJ

Editorial: Screening high risk populations for lung cancer

News Release: US lung cancer screening linked to earlier diagnosis and better survival – British Medical Journal

Related:

Screening for Lung Cancer: CHEST Guideline and Expert Panel Report.

USPSTF Statement: begin screening for lung cancer at age 50 years instead of 55 years for patients at risk

Meta-analysis: Lung cancer screening using low-dose computed tomography reduces lung cancer–specific mortality, albeit with a tradeoff of likely overdiagnosis

 

Commentary on Twitter

 


Multicenter comparative accuracy trial: Dynamic contrast-enhanced CT vs. positron emission tomography CT to characterize solitary pulmonary nodules.

16 Mar, 2022 | 08:51h | UTC

Abstract: Dynamic contrast-enhanced CT compared with positron emission tomography CT to characterise solitary pulmonary nodules: the SPUtNIk diagnostic accuracy study and economic modelling – Health Technology Assessment

Download: Full Report

 


Review: Current surgical indications for non-small-cell lung cancer.

11 Mar, 2022 | 08:39h | UTC

Current Surgical Indications for Non-Small-Cell Lung Cancer – Cancers

 


RCT: Role of thoracic ultrasonography in pleurodesis pathways for malignant pleural effusions.

8 Mar, 2022 | 08:28h | UTC

Role of thoracic ultrasonography in pleurodesis pathways for malignant pleural effusions (SIMPLE): an open-label, randomised controlled trial – The Lancet Respiratory Medicine (link to abstract – $ for full-text)

 

Commentary on Twitter

 


RCT: In patients with early-stage lung cancer, video-assisted thoracoscopic lobectomy is associated with better recovery of physical function at 5 weeks.

3 Mar, 2022 | 08:42h | UTC

Video-Assisted Thoracoscopic or Open Lobectomy in Early-Stage Lung Cancer – NEJM Evidence

 

Commentary on Twitter

 


SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumors.

3 Mar, 2022 | 08:08h | UTC

SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021) – Clinical and Translational Oncology

 


ASCO Guideline Update: Adjuvant systemic therapy and adjuvant radiation therapy for stage I-IIIA completely resected non–small-cell lung cancer.

23 Feb, 2022 | 10:08h | UTC

Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I-IIIA Completely Resected Non–Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update – Journal of Clinical Oncology

Commentary: Rapid Guideline Revises Recommendations for Adjuvant Therapy in Patients With Early-Stage Lung Cancer – ASCO Daily News

 

Commentary on Twitter

 


Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

7 Feb, 2022 | 08:36h | UTC

Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology – Journal of the National Comprehensive Cancer Network

 


Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer.

4 Feb, 2022 | 08:38h | UTC

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer – Journal of Clinical Oncology

Original Study: Randomized Trial: Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

 


RCT: Sugemalimab improves progression-free survival vs. placebo in patients with metastatic non-small-cell lung cancer.

1 Feb, 2022 | 08:25h | UTC

Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial – The Lancet Oncology (link to abstract – $ for full-text)

Related study: Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

Commentaries:

Sugemalimab shows promise for locally advanced, metastatic NSCLC – Medicine Matters

Sugemalimab Boosts Outcomes in NSCLC – MedPage Today (free registration required)

 

Commentary on Twitter

 


Systematic Review: Immunotherapy (excluding checkpoint inhibitors) for stage I to III non‐small cell lung cancer treated with surgery or radiotherapy with curative intent.

27 Jan, 2022 | 09:15h | UTC

Immunotherapy (excluding checkpoint inhibitors) for stage I to III non‐small cell lung cancer treated with surgery or radiotherapy with curative intent – Cochrane Library

 


Stay Updated in Your Specialty

No spam, just news.